<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TRIHEXYPHENIDYL HYDROCHLORIDE</span><br/>(trye-hex-ee-fen'i-dill)<br/><span class="topboxtradename">Aparkane <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Apo-Trihex <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Novohexidyl <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Trihexy<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">anticholinergic (parasympatholytic)</span>; <span class="classification">antiparkinsonism agent</span>; <span class="classification">anti-muscarinic</span>; <span class="classification">antispasmodic</span><br/><b>Prototype: </b>Atropine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2 mg, 5 mg tablets; 5 mg sustained release capsules; 2 mg/5 mL elixir</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic tertiary amine anticholinergic agent similar to atropine. Thought to act by blocking excess of acetylcholine at
         certain cerebral synaptic sites. Relaxes smooth muscle by direct effect and by atropinelike blocking action on the parasympathetic
         nervous system.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Anticholinergic agent diminishes the characteristic tremor of Parkinson's disease. Antispasmodic action appears to be one-half
         that of atropine.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Symptomatic treatment of all forms of parkinsonism (arteriosclerotic, idiopathic, postencephalitic). Also to prevent or control
         drug-induced extrapyramidal disorders.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Huntington's chorea, spasmodic torticollis.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Narrow-angle glaucoma. Safety during pregnancy (category C), lactation, or in children is not established.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>History of drug hypersensitivities; arteriosclerosis; hypertension; cardiac disease, kidney or liver disorders; obstructive
         diseases of GI or genitourinary tracts; older adults with prostatic hypertrophy.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Parkinsonism</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1 mg day 1, 2 mg day 2, then increase by 2 mg q35d up to 610 mg/d in 3 or more divided doses (max: 15 mg/d)<br/><br/><span class="indicationtitle">Extrapyramidal Effects</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 515 mg/d in divided doses<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give before or after meals, depending on how patient reacts. Older adults and patients prone to excessive salivation (e.g.,
            postencephalitic parkinsonism) may prefer to take drug after meals. If drug causes excessive mouth dryness, it may be better
            given before meals, unless it causes nausea.
         </li>
<li>Once stabilized on conventional dosage forms, patient may be switched to sustained-release capsules to permit once- or twice-a-day
            dosing.
         </li>
<li>Do not crush or chew sustained-release capsules. These must be swallowed whole.</li>
<li>Store at 15°30° C (59°86° F) in tight container unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> GI:</span> <span class="speceff-common">Dry mouth, nausea,</span> constipation. <span class="typehead">Special Senses:</span> <span class="speceff-common">Blurred vision,</span> mydriasis, photophobia, angle-closure glaucoma. <span class="typehead">Urogenital:</span> Urinary hesitancy or retention. <span class="typehead">CNS:</span> <span class="speceff-common">Dizziness, nervousness,</span> insomnia, drowsiness, confusion, agitation, delirium, psychotic manifestations, euphoria. <span class="typehead">CV:</span> Tachycardia, palpitations, hypotension, orthostatic hypotension. <span class="typehead">Body as a Whole:</span> Hypersensitivity reactions. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Reduces therapeutic effects of <b>chlorpromazine,</b> <b>haloperidol,</b> <span class="classification">phenothiazines</span>; increases bioavailability of <b>digoxin;</b> <span class="classification">mao inhibitors</span> potentiate actions of trihexyphenidyl. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Onset:</span> Within 1 h. <span class="typehead">Peak:</span> 23 h. <span class="typehead">Duration:</span> 612 h. <span class="typehead">Elimination:</span> Excreted in urine. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Be aware that incidence and severity of adverse effects are usually dose related and may be minimized by dosage reduction.
            Older adults appear more sensitive to usual adult doses.
         </li>
<li>Monitor vital signs. Pulse is a particularly sensitive indicator of response to drug. Report tachycardia, palpitations, paradoxical
            bradycardia, or fall in BP.
         </li>
<li>Assess for and report severe CNS stimulation (see <small>ADVERSE EFFECTS</small>) that occurs with high doses, and in patients with arteriosclerosis, or those with history of hypersensitivity to other drugs.
         </li>
<li>In patients with severe rigidity, tremors may appear to be accentuated during therapy as rigidity diminishes.</li>
<li>Monitor daily I&amp;O if patient develops urinary hesitancy or retention. Voiding before taking drug may relieve problem.</li>
<li>Check for abdominal distention and bowel sounds if constipation is a problem.</li>
<li>Monitor intraocular pressure at regular intervals.</li>
<li>Provide close follow-up care. Tolerance may develop, necessitating dosage adjustment or use of combination therapy. Patients
            <img src="../images/special/greaterorequal.gif"/>60 y frequently develop sensitivity to drug action.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn measures to relieve drug-induced dry mouth; rinse mouth frequently with water and suck ice chips, sugarless gum, or
            hard candy. Maintain adequate total daily fluid intake.
         </li>
<li>Avoid excessive heat because drug suppresses perspiration and, therefore, heat loss.</li>
<li>Do not to engage in potentially hazardous activities requiring alertness and skill. Drug causes dizziness, drowsiness, and
            blurred vision. Help walking may be indicated.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>